DataMeds AI, Inc. has made a strategic move by entering into an Intellectual Property License and Product and Services Agreement with REBOOT Health AI, Inc. This agreement, effective October 13, 2026, allows DataMeds to leverage REBOOT's AI platform in its direct-to-consumer weight management business.
The licensing agreement is significant as it positions DataMeds to enhance its service offerings in the competitive landscape of the wholesale drugs industry. By utilizing advanced technology, the company aims to improve its market presence and operational efficiency.
Background
DataMeds AI, Inc. operates in the wholesale drugs sector, specifically under the SIC code 5122, which includes proprietary drugs and sundries. The company trades on the Nasdaq under the ticker symbol MEDS. Recent filings indicate that DataMeds has been active in restructuring its financial obligations, including converting vendor payables into equity and addressing compliance issues with Nasdaq.
What the Filing Says
According to the filing, "On October 13, 2026, DataMeds AI, Inc. entered into an Intellectual Property License and Product and Services Agreement with REBOOT Health AI, Inc." This agreement grants DataMeds an exclusive license to use REBOOT’s technology within a defined scope, specifically for managing GLP-1 users in its weight management business.
The agreement also includes a revenue-sharing component, where REBOOT will receive a portion of DataMeds' adjusted gross revenue generated from the use of the REBOOT technology.
Impact
This licensing agreement may significantly impact DataMeds' operations and its ability to attract customers in the weight management sector. By integrating REBOOT's AI capabilities, DataMeds could improve its service delivery and customer engagement. Furthermore, the agreement addresses a critical need for innovation in the wholesale drugs industry, where technology is becoming increasingly vital.
Additionally, the company is working to rectify its stockholder equity deficiency, which had previously put its Nasdaq listing at risk. The recent equity transactions, including the issuance of shares to REBOOT, are steps toward compliance with Nasdaq’s listing requirements.
What's Next
The filing does not specify what happens next, but DataMeds is expected to continue its efforts to meet Nasdaq's compliance standards while leveraging the new technology from REBOOT to enhance its product offerings.